会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明公开
    • THERAPEUTIC AGENTS FOR ALLERGIC DISEASES
    • 治疗过敏性疾病的药物
    • EP1101496A1
    • 2001-05-23
    • EP99929876.3
    • 1999-07-16
    • FUJI YAKUHIN KOGYO KABUSHIKI KAISHA
    • IGETA, Katsuhiro, Fuji Yakuhin Kogyo K.K.TOBETTO, Kenji, Maruho R+D LaboratoriesSAIKI, IkuoODAKE, Shinjiro, Fuji Yakuhin Kogyo K.K.FUJISAWA, Tetsunori, Fuji Yakuhin Kogyo K.K.MATSUO, Tetsu, Maruho Co., Ltd.OKU, Tohru, Fuji Yakuhin Kogyo K.K.
    • A61K45/00
    • C07C279/18A61K31/00C07C259/06
    • Disclosed are anti-inflammatory agents, antiallergic agents, particularly prophylactically and/or therapeutically effective drugs for type I and/or IV allergic conditions, and further pharmaceutical drugs for prophylactically and/or therapeutically treating bronchial asthma, atopic diseases, etc. The inventive drugs comprising a prophylactically and/or therapeutically effective amount of a metalloproteinase inhibitor are active in the prophylaxis and/or therapy of allergy, especially type I and/or IV allergy, etc. The drugs are active in prophylactically and/or therapeutically treating inflammation, rhinitis, conjunctivitis, bronchial asthma, atopic diseases (including dermatitis, enteritis, etc.), or allergic gastroenterocolitis (allergic inflammation in digestive tract). The application of such drugs leads to (A) reduction of cells (such as lymphocytes, neutrophils, mast cells, eosinophils, basophils, macrophages and monocytes) at a diseased site, and/or (B) alleviation of inflammatory symptoms caused by migration, infiltration or accumulation of cells (such as lymphocytes, neutrophils, mast cells, eosinophils, basophils, macrophages and monocytes) to (or at) the diseased site, (C) inhibition of pathophysiological functions in cells (such as lymphocytes, neutrophils, mast cells, eosinophils, basophils, macrophages, monocytes, Langerhans cell and dendritic cells), and/or (D) reducing the blood level or inhibiting the production, of antibodies, especially IgE. Accordingly, the drugs are useful in the prophylaxis and/or therapy of diseases, disorders or ill conditions at the site.
    • 公开了用于I型和/或IV型变应性病症的抗炎剂,抗过敏剂,特别是预防和/或治疗有效的药物,以及用于预防和/或治疗性治疗支气管哮喘,特应性疾病等的其它药物。本发明的药物 包含预防和/或治疗有效量的金属蛋白酶抑制剂在预防和/或治疗变态反应,特别是I型和/或IV变态反应等方面具有活性。所述药物在预防和/或治疗性治疗炎症,鼻炎 ,结膜炎,支气管哮喘,特应性疾病(包括皮炎,肠炎等)或过敏性胃肠炎(消化道过敏性炎症)。 这些药物的应用导致(A)在患病部位细胞(如淋巴细胞,嗜中性粒细胞,肥大细胞,嗜酸性粒细胞,嗜碱性粒细胞,巨噬细胞和单核细胞)减少,和/或(B)缓解由迁移引起的炎症症状, 细胞(例如淋巴细胞,嗜中性粒细胞,肥大细胞,嗜酸性粒细胞,嗜碱性粒细胞,巨噬细胞和单核细胞)向病变部位(或其)的浸润或积聚,(C)细胞中的病理生理功能的抑制(例如淋巴细胞,嗜中性粒细胞,肥大细胞 ,嗜酸性粒细胞,嗜碱性粒细胞,巨噬细胞,单核细胞,朗格汉斯细胞和树突细胞)和/或(D)降低血液水平或抑制抗体特别是IgE的产生。 因此,这些药物可用于预防和/或治疗该部位的疾病,病症或病症。
    • 8. 发明公开
    • NOVEL PROTEIN AND MONOCLONAL ANTIBODY SPECIFIC THERETO
    • 胶原蛋白基质金属蛋白酶在GEGEN DIESE GERICHTETE MONOKLONALEANTIKÖRPER
    • EP0870826A1
    • 1998-10-14
    • EP96923081.2
    • 1996-07-12
    • FUJI YAKUHIN KOGYO KABUSHIKI KAISHA
    • SEIKI, MotoharuSATO, Hiroshi Heiwashukusha C57-11SHINAGAWA, Akira Fuji Yakuhin Kogyo Kabushiki
    • C12N9/64C12N15/00C12P21/08C12Q1/68
    • C12N9/6491A61K38/00C07K16/40Y02A50/473
    • A novel protein which is useful as diagnostic means for the studies relating to the diagnosis and treatment of cancer (detection of cancer cells, estimation of the malignity, etc.) and in other medicinal and physiological purposes; a gene encoding the same; and an antibody, in particular, a monoclonal antibody specific to the protein. MT-MMP-3, which is a pro MMP-2 activator having the ability to activate pro MMP-2 which is under expression specifically on the surface layer of a human cancer cell and falling within the category of MMP but being different from MT-MMP-1; a DNA containing the base sequence encoding the same; host cells transformed by the DNA; a process for producing a matrix metalloproteinase protein by using the host cells; a monoclonal antibody binding specifically to the matrix metalloproteinase protein; and use of the protein and antibody.
    • 一种新的蛋白质,可用于诊断和治疗癌症(癌症细胞的检测,恶性肿瘤的估计等)和其他药物和生理学目的的诊断手段; 编码该基因的基因; 特别是抗体,特别是针对蛋白质的单克隆抗体。 MT-MMP-3是具有活化pro MMP-2的能力的亲MMP-2激活剂,其特异性地表达在人类癌细胞的表面上,并且属于MMP类别,但不同于MT- MMP-1; 含有编码其的碱基序列的DNA; 由DNA转化的宿主细胞; 通过使用宿主细胞产生基质金属蛋白酶蛋白质的方法; 与基质金属蛋白酶蛋白特异性结合的单克隆抗体; 并使用蛋白质和抗体。